HTLV-1 اثرات درماني دانازول در مبتلايان به ميلوپاتي ناشي از

The Comparative Therapeutic Effects of Danazol with Multivitamin in HTLV-1 Associated Myelopathy

Introduction: HTLV-1 Associated myelopathy (HAM) is one of the endemic diseases of the north of Khorasan province and usually manifests as a clinical syndrome of chronic progressive spastic paraparesis. Most proposed treatments in HAM are symptomatic but a few etiological treatments such as Danazol is considered. Material and Methods: This ia a "before and after clinical trial" study. Only 53 patients of 61 patients in which the HAM were documented by MRI, blood & CSF serology and PCR, and CSF cytology and biochemistry, qualified to admitted in this study. Before adminstration of drugs and along the treatment period the severity of symptoms and motor disability (According to Motor Disability Grading) were appraised monthly for 6 months. Results: Among 38 patients in the first group who were treated with danazol after 6 months the difference between MDGo and MDGe (indicator of motor disability improvement) was 0.89, but there was no difference between MDGo and MDG6 among the other group who were treated with multivitamin (PO.001). Considering subjective findings and satisfaction of patients comparing symptoms such as Pain, parestesia, muscular stiffness and gate and Urinary difficulties there was a significant difference between these two groups. Of course the validity of test was more for muscular stiffness (PO.001) and less for parestesia (P=0.348). Conclusion:T\m study revealed that Danazol has a partial effect on improvement of motor disability and symptoms of HAM; and as there are much less side effect for Danazol than other regimens such as corticostroids and cytotoxic drugs it can be proposed, but the efficacy of danazol maybe less than these regimens.